LON:MPH Mereo BioPharma Group plc (MPH.L) (MPH) Share Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range 26.50▼ 26.5052-Week Range N/AVolume49,264 shsAverage Volume333,975 shsMarket Capitalization£89.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Mereo BioPharma Group plc (MPH.L) alerts: Email Address Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Mereo BioPharma Group plc (MPH.L) Stock (LON:MPH)Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.Read More Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << MPH Stock News HeadlinesSeptember 5 at 11:04 AM | thestreet.comMereo BioPharma Group plcAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mereo Biopharma on Strong Clinical and Financial ProspectsSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.July 19, 2024 | finance.yahoo.comMereo BioPharma Group plc (MAH0.F)May 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), GoodRx Holdings (GDRX) and NewAmsterdam Pharma Company (NAMS)April 14, 2024 | morningstar.comMereo BioPharma Group PLC ADR MREOFebruary 24, 2024 | msn.comMereo BioPharma Group plc - Depositary Receipt () (MREO) Price Target Increased by 17.65% to 5.10February 23, 2024 | benzinga.comMereo BioPharma Group Stock (NASDAQ:MREO), Insider Trading ActivitySeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.February 22, 2024 | wsj.comMereo BioPharma Group PLC ADRJanuary 8, 2024 | msn.comMereo BioPharma provides update on pipeline progress, reaffirms cash runway guidanceJanuary 8, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Mereo Biopharma Group Plc (MREO)January 8, 2024 | markets.businessinsider.comMereo BioPharma Provides Update on Pipeline Progress and Corporate DevelopmentsDecember 13, 2023 | seekingalpha.comMereo BioPharma: Lagging Stock Despite Positive DataOctober 23, 2023 | markets.businessinsider.comMereo BioPharma Reports on Recent Program Developments and Provides Financial UpdateJune 14, 2023 | markets.businessinsider.comSVB Securities Sticks to Its Buy Rating for Mereo Biopharma Group Plc (MREO)June 6, 2023 | msn.comUltragenyx, Mereo shares gain after positive results from study of bone disorder treatmentJune 6, 2023 | msn.comUltragenyx, Mereo gain on Phase 2 data for bone disorder therapySee More Headlines Receive MPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group plc (MPH.L) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/29/2020Today9/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:MPH CUSIPN/A CIKN/A Webmereobiopharma.com Phone44 33 3023 7300FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio164.26 Current Ratio2.98 Quick Ratio2.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow1.55 Book ValueGBX 7.20 per share Price / BookN/AMiscellaneous Outstanding Shares338,713,984Free FloatN/AMarket Cap£89.76 million OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Denise Scots-Knight (Age 61)Co-Founder, CEO & Exec. Director Comp: $751.37kMr. Charles Sermon (Age 51)Co-Founder, Gen. Counsel & Company Sec. Comp: $545.68kDr. Alastair MacKinnon (Age 50)Co-Founder & Chief Medical Officer Comp: $540.12kMr. John Richard (Age 63)Co-Founder & Head of Corp. Devel. Comp: $512.99kMr. Michael Stephen Wyzga MBA (Age 65)Interim CFO & Exec. Director Comp: $27.59kMs. Alexandra Hughes-Wilson (Age 49)Head of Patient Access & Commercial Planning Comp: $265.93kMs. Jill Henrich (Age 57)US Site Head & Sr. VP of Regulatory Affairs Comp: $286.93kDr. John A. Lewicki (Age 68)Chief Scientific Officer Dr. Fiona BorHead of Intellectual PropertyMr. Ian HodgsonHead of Clinical OperationsMore ExecutivesKey CompetitorsPureTech HealthLON:PRTCOxford BiomedicaLON:OXBHorizon Discovery Group plc (HZD.L)LON:HZDAvacta GroupLON:AVCTFaron Pharmaceuticals OyLON:FARNView All Competitors MPH Stock Analysis - Frequently Asked Questions How were Mereo BioPharma Group plc (MPH.L)'s earnings last quarter? Mereo BioPharma Group plc (MPH.L) (LON:MPH) posted its earnings results on Tuesday, September, 29th. The company reported ($105.00) earnings per share for the quarter. How do I buy shares of Mereo BioPharma Group plc (MPH.L)? Shares of MPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Mereo BioPharma Group plc (MPH.L) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group plc (MPH.L) investors own include Enanta Pharmaceuticals (ENTA), Advanced Micro Devices (AMD), American Tower (AMT), Inovio Pharmaceuticals (INO), Micron Technology (MU), Tesla (TSLA) and Amgen (AMGN). This page (LON:MPH) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc (MPH.L) Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group plc (MPH.L) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.